Myoclonic cerebellar dyssynergia
diseaseOn this page
Also known as cerebelloparenchymal disorder type 5cerebelloparenchymal disorder VCPD5dentate cerebellar ataxiadentatorubral atrophydyssynergia cerebellaris myoclonicadyssynergia cerebellaris progressivamyoclonus and ataxiaprimary dentatum atrophyprogressive myoclonus ataxiaRamsay Hunt cerebellar syndromeRamsay Hunt syndromeRamsay Hunt syndrome type 1Ramsay Hunt syndrome type 1 (formerly)
Summary
Myoclonic cerebellar dyssynergia (MONDO:0008945) is a disease and 1 clinical trial. A subtype of cerebelloparenchymal disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | myoclonic cerebellar dyssynergia |
| Mondo ID | MONDO:0008945 |
| EFO | EFO:1001053 |
| MeSH | D002527 |
| OMIM | 159700, 213400 |
| DOID | DOID:12707 |
| SNOMED CT | 73495003 |
| UMLS | C3489626 |
| MedGen | 483579 |
| GARD | 0009256 |
| Is cancer (heuristic) | no |
Also known as: cerebelloparenchymal disorder type 5 · cerebelloparenchymal disorder V · CPD5 · dentate cerebellar ataxia · dentatorubral atrophy · dyssynergia cerebellaris myoclonica · dyssynergia cerebellaris progressiva · myoclonus and ataxia · primary dentatum atrophy · progressive myoclonus ataxia · Ramsay Hunt cerebellar syndrome · Ramsay Hunt syndrome · Ramsay Hunt syndrome type 1 · Ramsay Hunt syndrome type 1 (formerly)
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › cerebelloparenchymal disorder › myoclonic cerebellar dyssynergia
Related subtypes (1): spinocerebellar ataxia type 17
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 1.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06542289 | Not specified | NOT_YET_RECRUITING | Safety and Effectiveness of the BlinkER System in Participants With Facial Nerve Palsy |
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.